RLYB.US Rallybio Corp

Healthcare Biotechnology USA Stocks
15.29 USD
Close of Nov 18, 2026
3.67 17.57
Market cap
USD 85.6M
P/E
3.3x
P/B
0.94x
ROE
47.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RLYB.US undervalued?

Graham number
Price15.29
Graham value41.08
Discount62.8%

RLYB.US trades 62.8% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rallybio Corp fundamental analysis

No fundamental analysis for Rallybio Corp yet.

Rallybio Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rallybio Corp

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and…

Full company profile